UAE Generic Drugs Market By Type (Small Molecule Generics, Biosimilars), By Mode of Drug Delivery (Oral, Topical, Parenteral, Others), By Form (Tablet, Capsule, Injection, Others), By Source (In House, Contract Manufacturing Organizations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Anti-Inflammatory Diseases, Others), By Region, Competition, Opportunities & Forecast, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 5.37 Billion
CAGR (2026-2031)	6.44%
Fastest Growing Segment	Biosimilars
Largest Market	Abu Dhabi
Market Size (2031)	USD 7.81 Billion

Market Overview

The UAE Generic Drugs Market will grow from USD 5.37 Billion in 2025 to USD 7.81 Billion by 2031 at a 6.44% CAGR. Generic drugs are pharmaceutical products bioequivalent to their brand-name counterparts, containing the same active ingredients, dosage, strength, and route of administration, becoming available after patent expiry. The UAE Generic Drugs Market is driven by several factors, including the increasing prevalence of chronic diseases requiring affordable treatment options, proactive government initiatives promoting local manufacturing, and enhanced healthcare accessibility. For instance, according to recent industry insights, there are 6,176 generic medicines available in the UAE's pharmaceutical market, reflecting a robust supply base. Additionally, rising healthcare expenditure and a growing population further stimulate demand for cost-effective therapeutic solutions.

However, the market faces a significant challenge in the form of intense competition among numerous domestic and international manufacturers. This competitive landscape necessitates strategic differentiation and continuous innovation to maintain market share and profitability amidst price sensitivity and evolving regulatory standards.

Key Market Drivers

Policy measures to expand local production and reduce drug costs
The UAE Generic Drugs Market is significantly influenced by robust government initiatives aimed at enhancing affordability and boosting local pharmaceutical production. These strategic endeavors are designed to reduce reliance on imports and stabilize drug supply chains, thereby making essential medicines more accessible and cost-effective for the populace. For example, according to Research and Markets, in October 2025, in the "Middle East Pharmaceutical Market Report 2025-2033," the UAE government aims to expand local drug production capacity by 40% in the upcoming year, fostering a more self-reliant healthcare system. Additionally, the Emirates Drug Establishment activated a mechanism in February 2026 requiring pharmaceutical companies to appoint multiple authorized local agents for each product, which is intended to increase competition and further reduce medicine costs for consumers.

Chronic disease burden driving demand and local manufacturing capacity
The increasing prevalence of chronic diseases also serves as a substantial driver for the UAE Generic Drugs Market, necessitating a greater availability of affordable and effective treatment options. Conditions such as diabetes, cardiovascular diseases, and obesity place a considerable burden on the healthcare system and individuals. According to Zavis, in April 2026, the UAE's diabetes prevalence rate stands at roughly 16.3% of the adult population, underscoring the widespread demand for long-term medication management. This consistent demand for chronic disease management drugs supports the sustained growth of the generic segment. Overall, according to an industry insights summary, in May 2026, there are 23 pharmaceutical manufacturing centers in the UAE, demonstrating a foundational capability for local supply.

Download Free Sample Report

Key Market Challenges

Intense competition erodes margins and growth prospects
The UAE Generic Drugs Market faces a significant challenge in the form of intense competition among numerous domestic and international manufacturers. This highly competitive landscape directly hampers market growth by driving aggressive pricing strategies and increasing price sensitivity among both consumers and healthcare providers. As a result, manufacturers experience substantial pressure to reduce product costs, which directly erodes profit margins and complicates the maintenance of sustainable operations within the sector.

Price reductions constrain revenue and expansion capital
The need to compete effectively on price in this saturated environment necessitates frequent adjustments to product valuations. For instance, according to the Emirates Drug Establishment, in May 2026, retail prices for 168 pharmaceutical products across the UAE were reduced by approximately 5% to 60%. Such considerable price reductions, influenced by the imperative for market differentiation and affordability, directly limit the revenue potential for generic drug manufacturers. This persistent pressure to compete primarily on cost restricts capital available for new product development and broader market expansion, thereby hindering the overall growth trajectory of the UAE generic drugs sector.

Key Market Trends

Biosimilars as a Growth Driver in UAE Generics
The increasing adoption of biosimilars represents a significant trend within the UAE generic drugs market, driven by the imperative to manage healthcare costs and expand patient access to advanced therapies. As patent expiries for originator biological drugs increase, biosimilars offer cost-effective alternatives with comparable efficacy and safety profiles. This trend is gaining momentum as healthcare providers and payers recognize their value in reducing the financial burden of chronic and complex disease management. For instance, according to the "Pharmaceutical Landscape in the GCC: Key Insights and Statistics (2026)", in May 2026, biosimilars are expected to grow at a remarkable 15-20% Compound Annual Growth Rate, particularly in oncology and immunology, across the GCC region. This growth reflects a broader regional shift towards embracing these advanced generic forms.

E-Pharmacy Expansion and Digital Health Investment in the UAE
Further impacting the market is the digital transformation in pharmaceutical access, notably through the expansion of e-pharmacy services. This shift provides enhanced convenience for consumers seeking both prescription and over-the-counter medications, facilitating broader reach and improving medication adherence. E-pharmacy platforms leverage digital infrastructure to offer services like online consultations and home delivery, aligning with evolving consumer preferences for accessible healthcare solutions. The Ministry of Health and Prevention in the UAE, according to Spectronix Consultancy, in June 2026, in the "MOH UAE Unveils Ambitious 2026 Healthcare Innovation Strategy," plans to invest over AED 500 million in digital health infrastructure by the end of 2026, aiming for a 30% increase in telemedicine consultations across the nation. This substantial investment underscores the government's commitment to digitalizing healthcare, which directly benefits the e-pharmacy segment of the generic drugs market.

Segmental Insights

Biosimilars: Growth Driven by Cost-Effectiveness and Regulatory Support
In the UAE Generic Drugs Market, Biosimilars represent the fastest-growing segment, primarily driven by their significant cost-effectiveness compared to originator biologics. This affordability enhances patient access to essential treatments for chronic conditions such as rheumatoid arthritis and cancer, while also supporting broader healthcare expenditure management. The rapid expansion is further bolstered by the strong regulatory framework established by the Ministry of Health and Prevention (MOHAP), which aligns with international guidelines from bodies like the World Health Organization and the European Medicines Agency, ensuring biosimilar quality, safety, and efficacy. Additionally, government initiatives actively promote the adoption of biosimilars in public healthcare facilities, contributing to their accelerated market penetration.

Regional Insights

Abu Dhabi's dominant position in the UAE generic drugs market, driven by infrastructure, population density, and the DOH framework.
Abu Dhabi leads the UAE Generic Drugs Market due to its robust and advanced healthcare infrastructure. The emirate's higher population density contributes significantly to increased pharmaceutical consumption, driving demand for generic medications. The Department of Health (DOH) Abu Dhabi plays a pivotal role, operating its own comprehensive drug authorization framework in parallel with the federal system, and maintaining an extensive approved drug formulary, which streamlines access to essential medicines. Furthermore, governmental initiatives and the Abu Dhabi Economic Vision 2030 prioritize enhancing healthcare services and promoting local pharmaceutical availability, solidifying Abu Dhabi's dominant position in the generic drug sector.

Recent Developments

• In March 2025, Gulf Pharmaceutical Industries (Julphar), a leading pharmaceutical company in the MENA region, announced an exclusive licensing partnership with Dong-A ST, a reputable South Korean pharmaceutical firm. Under this agreement, Julphar obtained the rights to exclusively tech transfer, manufacture, and commercialize a Darbepoetin Alfa biosimilar across the MENA region. This collaboration was a key step in Julphar’s strategy to expand its biologics portfolio, enhancing access to innovative and high-quality generic healthcare solutions within the UAE and the broader region.
• In January 2025, Globalpharma, a leading UAE-based pharmaceutical manufacturer and a wholly owned subsidiary of Dubai Investments PJSC, announced plans to introduce 25 innovative products throughout the year. These new launches were strategically planned for key therapeutic areas, including diabetes, cardiovascular health, gastroenterology, and orthopedics. This ambitious rollout demonstrated Globalpharma’s dedication to providing high-quality, accessible medications and expanding its presence in the UAE generic drugs market, building on its prior successes in delivering essential treatments.
• In March 2024, Mubadala Investment Company PJSC, a state-owned global investment firm, entered a definitive agreement to acquire KELIX Bio Limited. KELIX Bio focuses on delivering complex generic drugs in emerging economies, an area vital for pharmaceutical accessibility. This acquisition was aimed at strengthening the development of the UAE's life science ecosystem, contributing to economic diversification. The strategic move supported the local manufacturing and supply of generic medications, further positioning the UAE as a significant player in the global life science sector.
• In January 2024, Globalpharma, a prominent pharmaceutical manufacturer in the UAE and a subsidiary of Dubai Investments PJSC, launched two new medications at DUPHAT 2024. The introductions included a herbal medicine, featuring a unique blend of cloves and costus, manufactured locally and inspired by UAE heritage. Additionally, the company added a new cardiovascular treatment, a combination of Rosuvastatin and Ezetimibe, for managing dyslipidemia. These product launches underscored Globalpharma’s commitment to expanding its diverse range of effective generic healthcare solutions within the UAE.

Key Market Players

• Gulf Pharmaceutical Industries
• Neopharma LLC
• Globalpharma Co. LLC
• Pharmax Pharmaceuticals FZ-LLC
• Gulf Inject LLC
• LifePharma FZE
• Medpharma LLC
• United Pharma
• Hikma Pharmaceuticals PLC
• Modern Pharmaceutical Company LLC

By Type	By Mode of Drug Delivery	By Form	By Source	By Distribution Channel	By Application	By Region
Small Molecule Generics Biosimilars	Oral Topical Parenteral Others	Tablet Capsule Injection Others	In House Contract Manufacturing Organizations	Hospital Pharmacies Retail Pharmacies Online Pharmacies	Cardiovascular Diseases Diabetes Neurology Oncology Anti-Inflammatory Diseases Others	Dubai Abu Dhabi Sharjah Rest of UAE

Report Scope:

In this report, the UAE Generic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• UAE Generic Drugs Market, By Type:

• Small Molecule Generics
• Biosimilars

• UAE Generic Drugs Market, By Mode of Drug Delivery:

• Oral
• Topical
• Parenteral
• Others

• UAE Generic Drugs Market, By Form:

• Tablet
• Capsule
• Injection
• Others

• UAE Generic Drugs Market, By Source:

• In House
• Contract Manufacturing Organizations

• UAE Generic Drugs Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

• UAE Generic Drugs Market, By Application:

• Cardiovascular Diseases
• Diabetes
• Neurology
• Oncology
• Anti-Inflammatory Diseases
• Others

• UAE Generic Drugs Market, By Region:

• Dubai
• Abu Dhabi
• Sharjah
• Rest of UAE